|Bid||53.80 x 1300|
|Ask||55.78 x 1800|
|Day's range||54.86 - 55.33|
|52-week range||44.35 - 56.22|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||67.39|
|Earnings date||30 Jan 2024 - 05 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||60.72|
Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.